Cmed Clinical Services Appoints New Chief Medical Officer
Cmed Clinical Services, an innovative, full service CRO providing services to the Biopharma industry worldwide, announced today the appointment of Dr. Bams Abila, MD, PhD, FFPM, to Chief Medical Officer.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151009005298/en/
In this role, Dr. Abila will be responsible for leading the development and operation of Cmed’s medical function, providing leadership and strategic guidance on medical and scientific matters. He will also provide general support and training to the medical and consulting groups across Cmed to ensure the safe, legal, ethical and optimal drug development design and conduct of clinical studies. He will be based in the UK and brings to Cmed a wealth of experience in the design and delivery of clinical strategies and clinical studies with small molecules and biologicals across several therapy areas in Phases I-III.
“We are delighted to welcome Bams Abila to Cmed” said Dr. David Connelly, Cmed’s CEO. “Bams brings a vast amount of expertise, knowledge and skills in translational medicine, clinical development and drug safety, which will be very valuable not only to Cmed in driving our plans for future growth, but for our clients in maintaining and enhancing the design and conduct of their clinical trials. Bams also has a deep interest in the use of advanced data technologies to enhance the speed and efficiency of drug development which fits very well with the evolution of Cmed’s technology division.”
Dr. Abila has 10 years academic medical research experience and extensive global drug development experience spanning 25 years across several therapeutic areas within pharmaceutical settings, including Aventis, Pfizer, Astellas, AstraZeneca and GSK. He is the Founder and Principal Consultant in Pharmaceutical Medicine of Clintreq Consultancy Ltd, working with both pharmaceutical and biotech companies. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK), Fellow of the Royal Society of Medicine (UK) and is a Member of the British Association of Pharmaceutical Physicians, the British Pharmacological Society and the American Heart Association. He is also a member of the American Society of Clinical Pharmacology and was a founding member of the society’s Biologics Community.
- ends -
Cmed is an innovative full service CRO and a software developer of smart e-clinical data capture and management technologies. Cmed was established in 2000 with the vision to conduct clinical trials better than anyone else, thus saving and helping lives. Cmed has a focus on bringing innovation to the design and conduct of clinical trials, including in the areas of clinical data capture, data management, monitoring. Cmed has two divisions: Cmed Clinical Services and Cmed Technology.
Cmed Clinical Services is a global CRO providing services to the Biopharma industry worldwide. Cmed works with clients to not only deliver the clinical trial services effectively, and with quality, passion, teamwork and superior customer service, but also, especially for full service projects, by understanding the clients commercial and business objectives. Cmed then leverages its in-depth expertise to ensure the development program and/or clinical trial is well designed and conducted as efficiently and as cost effectively as possible. Cmed has particular expertise in the design and conduct of complex, oncology and rare disease trials and the provision of Biometric functional services.
Cmed Technology designed and developed Timaeus: a unique single platform for electronic trial design, paper & electronic data capture, monitoring, coding, data management and reporting. Using distributed cloud computing and mobile technologies, Timaeus has been deployed in over 400 clinical trials and has successfully passed multiple audits. The unique Timaeus design provides a number of benefits to our clients including rapid database build (weeks not months), mid-trial updates without down-time and non-reliance on the internet. These benefits lead to many advantages including the removal of EDC build from study start-up, no restriction on investigator site selection, no negative impact on recruitment timelines due to design changes, and elevated investigator motivation.
Anna Forster, Marketing Manager
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
PROSUME23.9.2017 10:02 | pressemeddelelse
How to Share New Energy Models Through Blockchain?
MA-ICP-GROUP22.9.2017 22:23 | pressemeddelelse
California Sports Surfaces Announces New Senior Leadership
CQN-SMITHS-DETECTION22.9.2017 18:04 | pressemeddelelse
CORRECTING and REPLACING Smiths Detection Wins Biggest Ever Single Order for Next-Generation Hold Baggage Scanner for Frankfurt Airport
MA-ICP-CONSTRUCTION22.9.2017 16:39 | pressemeddelelse
California Sports Surfaces’ Rebound Ace Portable Court to be Used at Inaugural Laver Cup
SMITHS-DETECTION22.9.2017 13:02 | pressemeddelelse
Smiths Detection is Supplying the Latest Technology for ECAC Standard 3 EDS Upgrade at Frankfurt Airport
VESPA-INTERACTIVE22.9.2017 13:02 | pressemeddelelse
Mobile RPG ‘King’s Raid’ Set to Launch in European Markets
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum